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The African Esophageal Cancer 
Consortium: A Call to Action
Esophageal cancer is the eighth most common 
cancer worldwide and the sixth most common 
cause of cancer-related death; however, world-
wide incidence and mortality rates do not reflect 
the geographic variations in the occurrence 
of this disease.1 More than 80% of cases and 
deaths from esophageal cancer occur in devel-
oping countries, and geographically defined 
high-incidence regions are a striking and dis-
tinguishing characteristic of this malignancy. In 
contrast to the economically developed world, 
where the dominant subtype of esophageal can-
cer is adenocarcinoma, esophageal squamous 
cell carcinoma (ESCC) is the dominant subtype 
in high-incidence areas, including Africa.
High-incidence areas for ESCC have been known 
and studied for years in northern China, north-
eastern Iran, southern South America, and 
South Africa.2-9 Another geographically defined 
high-incidence area is the eastern corridor 
of Africa. The common occurrence of ESCC 
along this corridor was documented more than 
a half-century ago and mapped as far back 
as 1969.10 More recent evidence has demon-
strated that this region—extending from Ethio-
pia to South Africa—remains disproportionately 
impacted by the high incidence of ESCC.11,12 In 
stark contrast, esophageal cancer is much less 
common in Western or Northern Africa1 (Fig 1).
Reflecting the significant impact of ESCC in 
the developing world, the US National Cancer 
Institute (NCI) and the International Agency for 
Research on Cancer (IARC) convened an Inter-
national Tumor Workshop on Esophageal Squa-
mous Cell Carcinoma in September 2016.14 
Whereas this meeting was attended by interna-
tional experts who represented multiple high- 
incidence regions throughout the developing 
world, a substantial focus was on the emerging 
data and unmet needs related to the high inci-
dence of ESCC in sub-Saharan Africa. At this 
meeting, a critical mass of African investigators 
and their international partners initiated the Afri-
can Esophageal Cancer Consortium (AfrECC) to 
facilitate research collaborations in environmen-
tal, molecular, and genetic epidemiology; early 
detection, clinical management, treatment, and 
palliation; capacity building; and interventions to 
reduce the burden of ESCC in sub-Saharan Africa.
CURRENT AfrECC SITES
During the past few years, several groups have 
initiated epidemiologic and molecular studies of 
ESCC at sites in sub-Saharan Africa, including 
Dar es Salaam, Tanzania (Muhimbili University 
of Health and Allied Sciences, Ocean Road 
Cancer Institute, and University of California, 
San Francisco); Eldoret, Kenya (Moi University 
and IARC); Bomet, Kenya (Tenwek Hospital 
and NCI); Moshi, Tanzania (Kilimanjaro Clinical 
Research Institute and IARC); Lilongwe, Malawi 
(The University of North Carolina Project-Malawi 
and NCI); Blantyre, Malawi (Queen Elizabeth 
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Central Hospital and IARC); Lusaka, Zambia 
(Tropical Gastroenterology and Nutrition Group, 
University of Zambia); Addis Ababa, Ethiopia 
(Addis Ababa University and IARC); and Johan-
nesburg and Cape Town, South Africa (Univer-
sity of the Witwatersrand and University of Cape 
Town). These groups have now joined together 
in AfrECC (Fig 2) to share expertise, infrastruc-
ture, and resources and to ensure that all pres-
ent and future participant sites in sub-Saharan 
Africa fully benefit from our collaborative work. 
During regular conference calls, participants 
review ongoing activities, identify opportunities 
and challenges, and plan for the coordination 
of multisite efforts. In May 2017, AfrECC mem-
bers convened in East Africa and conducted 
visits to several AfrECC sites to learn from each 
other and facilitate closer collaboration. In the 
future, we aim to establish formal membership 
guidelines and pursue shared research fund-
ing to optimize the impact of our resources and 
efforts to reduce mortality and suffering from 
ESCC in this region.
CURRENT AfrECC PRIORITIES
Implement Coordinated Multisite Investigations 
Into the Etiology of ESCC in East Africa and 
Identify Targets for Primary Prevention
Studies from China and Iran, as well as from the 
United States, Europe, and Japan, demonstrate 
considerable etiologic heterogeneity for ESCC, with 
evidence that major risk factors in one population 
may play a more limited role in other populations. 
Whereas etiologic and genetic studies of esopha-
geal cancer in Asian populations have been rela-
tively extensive, the high-incidence region along the 
eastern corridor of Africa remains largely unstud-
ied. We recently conducted an extensive review to 
assess whether ESCC risk factors that have been 
established or are likely in other parts of the world 
are also present in the African context. Whereas 
many were identified, most have not been carefully 
studied in Africa.15 Moreover, in a number of East 
African populations, we observed a disproportion-
ate number (approximately 20%) of patients who 
were diagnosed at younger than 40 years old.12,16-19 
This high incidence of ESCC in patients younger 
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Fig 1. National-level 
map of age-standardized 
incidence rate (ASR) of 
esophageal squamous cell 
carcinoma in women and 
men (Arnold et al13).
than 40 years, as well as the geographic variation 
associated with this diagnosis, suggests plausible 
roles for unique environmental, infectious, and/or 
genetic risk factors in this region. Identification of 
environmental, molecular, and genetic factors, as 
well as possible interactions, that contribute to the 
high incidence of this disease along the eastern 
corridor of Africa will be necessary to inform pre-
vention and early detection strategies in this region.
Case control studies will be a primary method 
of etiologic research in this setting. A full case 
control study has completed accrual in Dar es 
Salaam, Tanzania,17 and smaller studies from 
Zambia20 and Ethiopia21 have been published. 
NCI and IARC are supporting several parallel 
ongoing case control studies at other AfrECC 
participant sites, collectively known as the ESC-
CAPE case control studies.22 At the three sites 
that began studies in 2016 and 2017, ques-
tionnaires have been harmonized and data are 
being collected electronically using a mobile 
health application, which helps standardize the 
data across sites, allows centralized and remote 
coordination, and improves real-time quality 
control. Whereas each individual site has the 
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Fig 2. Current participant 
sites in the African Esoph-
ageal Cancer Consortium 
(AfrECC).
potential to accrue hundreds of patients, no sin-
gle site is likely to identify the etiologic factors for 
the development of ESCC throughout the region, 
and no single study has the potential to confirm 
associations; thus, multisite collaborations with 
harmonized study instruments and protocols are 
needed to allow for comparison and validation of 
findings. Ultimately, we aim to merge data from 
multiple study sites to compare and contrast the 
etiological effects of lifestyle and environmental 
factors on ESCC across this region. Extensive 
questionnaire data and saliva and/or blood spec-
imens for future DNA analyses are being col-
lected from all study participants, and multisite 
genome-wide association studies, such as those 
previously conducted to investigate this disease 
in China,23 are planned.
Case control studies will seek to identify exposures 
that are implicated in ESCC in Africa; however, 
many associations will necessarily rely on self- 
reported data, as biomarker-based assessments 
are typically not feasible as a result of the severe 
alteration of the exposure—for example, diet—
caused by the disease. Thus, the consortium is 
also undertaking detailed ecologic and cross- 
sectional descriptive studies of specific expo-
sures, such as hot beverages24 and micronutri-
ent deficiencies,25 to understand major exposure 
sources, levels, and exposed population groups.
In addition, establishment of ESCC tumor biore-
positories for additional genomic profiling is 
underway. Mutation of the tumor suppressor 
gene, TP53, has been previously reported as 
the most frequent genetic alteration in ESCC 
in other settings,26,27 with mutation profiles that 
are known to vary across geographic areas28,29; 
however, a recent whole-exome sequencing and 
RNA sequencing analysis of 59 ESCC tumors 
from Malawi reported a high proportion of tumors 
without TP53 mutations, as well as a tumor 
mutation signature30 that is possibly consistent 
with an unknown carcinogenic exposure.31 This 
sequencing study from Malawi and case series 
from South Africa, Zambia, and Kenya have not 
supported an etiologic role for human papilloma-
virus,20,32-34 and, with rare exception,20,35 there is 
no evidence of an association of ESCC with HIV, 
either in time trends or in case control data36; 
however, a search for other possible infectious 
etiologies remains an area of active investigation.
Finally, we recognize that the sustainability and 
success of our research is ultimately dependent 
on the efforts of clinical and research colleagues 
in Africa, and we are committed to the provision 
of training in research methodology and longitu-
dinal mentoring to enhance and promote cancer 
research capabilities in the region.
Address the Impact of the Clinical Burden of 
Esophageal Cancer Through Capacity Building 
and Shared Resources in Treatment and 
Palliative Care
As in other low- and middle-income countries, 
patients with ESCC in eastern Africa present with 
advanced disease with symptoms of dyspha-
gia and obstruction and resultant malnutrition. 
Patients with ESCC are readily identifiable in 
surgical and medical hospital wards, profoundly 
wasted and holding spittoon cups to manage 
the secretion of saliva. The suffering of these 
patients is profound and weighs heavily on the 
minds of the physicians and nurses who care for 
them, many of whom share sentiments of help-
lessness and hopelessness because of the lack 
of available options for early detection, treatment 
or palliation.
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Meanwhile, at Tenwek Hospital, a community- 
based referral hospital in Bomet, Kenya, where 
ESCC accounts for 35% of all tumors, surgeons 
have deployed more than 2,000 self-expanding 
metal stents (SEMSs) for patients who present 
with esophageal obstruction. In a review of 1,000 
patients who received SEMSs, this technology 
was demonstrated to be safe and feasible for 
the palliation of dysphagia symptoms related to 
ESCC in resource-limited settings37; however, at 
most other sites in eastern Africa, the retail price 
for imported SEMSs is prohibitive for patients, a 
barrier that is compounded by the low socioeco-
nomic status and insufficient health insurance of 
these patients. As a result of financial barriers, the 
poor distribution of relatively inexpensive SEMSs, 
and inadequate endoscopy resources and train-
ing, palliative stenting is not widely available in 
eastern Africa. AfrECC is pursuing several options 
to support advocacy for equal and fair pricing and 
access to SEMS for the region, as well as capacity- 
building activities to support endoscopic training, 
including SEMS placement.
A recent report from China also suggests that 
steady, incremental progress may eventually yield 
high-impact programs for ESCC screening and 
earlier detection, which can significantly reduce 
mortality.38 With increased advocacy and aware-
ness about the high incidence of ESCC impact-
ing the region, we anticipate that earlier detection 
may yield an eventual trend toward increased 
numbers of patients presenting with tumors 
that are amenable to curative therapies, includ-
ing endoscopic therapy, chemoradiation, and/or 
surgery. We aim to support the development of 
standardized treatment protocols that are rele-
vant to the available resources within the region. 
The formation of surgical training partnerships 
will also facilitate training and the establishment 
of proficiencies in complex esophagectomy pro-
cedures. Finally, implementation strategies are 
needed to enhance and measure the acceptabil-
ity, feasibility, and sustainability of each of these 
interventions, and long-term monitoring is needed 
to evaluate their effects on clinical outcomes.
Heighten Awareness of ESCC Among physicians, 
At-Risk Populations, Policy Makers, and Funding 
Agencies
In the absence of the capacity to provide treat-
ment or palliation for patients with ESCC at most 
sites throughout eastern Africa, individuals who 
develop symptoms of dysphagia are commonly 
reticent to seek care, and there is a pervasive 
perception that going to the hospital with symp-
toms of dysphagia means certain death. Sadly, 
this perception is currently not far from reality, 
with patients routinely presenting with extremely 
advanced disease and at risk for rapid dete-
rioration; however, extrapolating from other 
diseases, increased awareness and education 
among at-risk populations and physicians may 
result in earlier presentations for clinical care, 
earlier diagnosis, and referrals to centers that 
are equipped to provide the necessary treat-
ment or palliation. In addition, increased advo-
cacy and awareness among local ministries of 
health and international funding agencies is 
critical for the provision of resources to increase 
access to relevant therapies and to support the 
necessary research to drive the development of 
evidence-based policies for prevention and palli-
ation. The priority activities of the consortium are 
summarized in Figure 3.
CONCLUSION
In May 2017, the World Health Assembly endorsed 
a set of measures to improve and scale up 
access to prevention, early diagnosis, prompt 
and accessible treatment, and palliative care 
for cancer.39 Member States called on WHO 
to promote access for all people to affordable 
cancer diagnosis and treatment and to provide 
countries with technical guidance to identify and 
implement priority cancer control interventions. 
WHO member states committed to ensuring 
adequate resources to support the implemen-
tation of national cancer control plans and to 
strengthen health systems to provide early diag-
nosis and treatment services for all patients with 
cancer. ESCC is one of the most prevalent and 
deadly cancers that afflicts eastern and southern 
Africa, and it is certainly one that puts vulnerable 
populations at risk for great morbidity and cata-
strophic health expenditures.
The task of scaling up care for ESCC within 
African health systems that are already fraught 
with challenges has been dismissed by some 
as impractical and unattainable because of 
the deadly nature of this disease. Whereas we 
acknowledge the challenges, our shared view is 
that this is the very attribute that makes this work 
urgent and imperative. We know from the evo-
lution of the HIV epidemic that etiologic under-
standing, palliation, health system strengthening, 
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capacity building, and the gradual implementa-
tion of effective prevention, early detection, and 
treatment interventions can provide a path for-
ward, even when faced with the most daunting 
of diseases.
Although international attention to the tremen-
dous burden of this disease is nascent, there is 
burgeoning high-quality work in progress at mul-
tiple sites in Kenya, Tanzania, Malawi, Zambia, 
Ethiopia, and South Africa, with the development 
of etiologic studies, biospecimen repositories, 
genome-wide association studies, and clinical 
training partnerships. Looking forward, we aim to 
enhance the ongoing efforts through increased 
collaboration across sites and strengthened 
international partnerships. Our call to action aims 
to raise awareness of the tremendous impact of 
this deadly disease on an already fragile region 
and to mobilize others to become involved.
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